Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Caspofungin Acetate

FDA-approved product (powder, intravenous), marketed as Cancidas, Caspofungin Acetate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Caspofungin Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Aspergillosis
  • Candidemia
  • Candidiasis
  • Fungal infectious disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antimycotics for systemic use
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J02AX04

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae, MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA65.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli53.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae57.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis61.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Caspofungin Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Caspofungin Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effects and Safety of Caspofungin and Corticosteroids in Pneumocystis Pneumonia in Non-HIV Patients

    NCT02603575 · start 2015-11

    Registered record
    Registry ID
    NCT02603575
    Conditions
    Pneumocystis Pneumonia
    Interventions
    caspofungin; corticosteroids; Sulfanilamides
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2015-11
    Completion
    Not recorded
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumocystis Pneumonia
    Interventioncaspofungin; corticosteroids; Sulfanilamides
    PhaseNot applicable
    Registry statusUnknown

  • Impact of a Loading Dose of Caspofungin in Invasive Candidiasis in ICU Patients

    NCT02413892 · start 2015-05

    Registered record
    Registry ID
    NCT02413892
    Conditions
    Candida Infections
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-05
    Completion
    2017-02
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandida Infections
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Optimal Dosage of Caspofungin in Critically Ill Patients

    NCT01994096 · start 2013-11

    Registered record
    Registry ID
    NCT01994096
    Conditions
    Critically Ill; Suspected Invasive Candidiasis
    Interventions
    Caspofungin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-11
    Completion
    2015-10
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCritically Ill; Suspected Invasive Candidiasis
    InterventionCaspofungin
    PhasePhase 4
    Registry statusCompleted

  • Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure

    NCT01968395 · start 2013-09

    Registered record
    Registry ID
    NCT01968395
    Conditions
    Bacterial Infections and Mycoses; Liver Disease
    Interventions
    Caspofungin 70 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-09
    Completion
    2014-10-21
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infections and Mycoses; Liver Disease
    InterventionCaspofungin 70 mg
    PhasePhase 4
    Registry statusCompleted

  • Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents

    NCT01686607 · start 2012-10-01

    Registered record
    Registry ID
    NCT01686607
    Conditions
    Systemic Fungal Infections
    Interventions
    Parenteral micafungin application; Other parenteral antifungal drugs
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-10-01
    Completion
    2018-04-30
    Enrolment
    40,110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSystemic Fungal Infections
    InterventionParenteral micafungin application; Other parenteral antifungal drugs
    PhaseNot recorded
    Registry statusCompleted

  • Empirical Versus Preemptive Antifungal Therapy

    NCT01288378 · start 2012-03

    Registered record
    Registry ID
    NCT01288378
    Conditions
    Fungal Infection; Leukemia; Myelodysplastic Syndromes
    Interventions
    caspofungin acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-03
    Completion
    2019-04-04
    Enrolment
    556

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFungal Infection; Leukemia; Myelodysplastic Syndromes
    Interventioncaspofungin acetate
    PhasePhase 3
    Registry statusCompleted

  • the Influence of Prophylactic and Empirical Anti-fungal Treatment in Severe Sepsis Patients With Perforations

    NCT02941068 · start 2012-03

    Registered record
    Registry ID
    NCT02941068
    Conditions
    Intra-abdominal Perforation
    Interventions
    fluconazole and caspofungin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-03
    Completion
    Not recorded
    Enrolment
    223

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntra-abdominal Perforation
    Interventionfluconazole and caspofungin
    PhasePhase 2
    Registry statusCompleted

  • Pharmacokinetics of Caspofungin (Cancidas ®) Given Intravenously as Therapy to Patients With an Invasive Fungal Infection in the Intensive Care Unit - a Search for Co-variates

    NCT01533558 · start 2012-01

    Registered record
    Registry ID
    NCT01533558
    Conditions
    Invasive Fungal Infection
    Interventions
    caspofungin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-01
    Completion
    2013-06
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Fungal Infection
    Interventioncaspofungin
    PhaseNot recorded
    Registry statusCompleted

  • Pharmacokinetic, Safety and Efficacy of Intermittent Application of Caspofungin for Antifungal Prophylaxis

    NCT01318148 · start 2011-04

    Registered record
    Registry ID
    NCT01318148
    Conditions
    Fungal Infection
    Interventions
    caspofungin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-04
    Completion
    2013-10
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFungal Infection
    Interventioncaspofungin
    PhasePhase 2
    Registry statusCompleted

  • A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074)

    NCT01165320 · start 2010-07-06

    Registered record
    Registry ID
    NCT01165320
    Conditions
    Candidiasis, Esophageal; Candidiasis, Invasive; Aspergillosis
    Interventions
    Caspofungin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-07-06
    Completion
    2013-09-17
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandidiasis, Esophageal; Candidiasis, Invasive; Aspergillosis
    InterventionCaspofungin
    PhasePhase 2
    Registry statusCompleted

  • Validation of an Index of Neutropenia (D-index) in Febrile Neutropenic Cancer Patients

    NCT00982540 · start 2010-02

    Registered record
    Registry ID
    NCT00982540
    Conditions
    Invasive Fungal Infections; Invasive Aspergillosis; Invasive Fusariosis
    Interventions
    caspofungin as preemptive antifungal therapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2010-02
    Completion
    2013-12
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Fungal Infections; Invasive Aspergillosis; Invasive Fusariosis
    Interventioncaspofungin as preemptive antifungal therapy
    PhaseNot applicable
    Registry statusTerminated

  • Effect of Weight and/or Obesity on Caspofungin Drug Concentrations

    NCT01062165 · start 2010-02

    Registered record
    Registry ID
    NCT01062165
    Conditions
    Obesity; Fungal Infection
    Interventions
    Caspofungin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-02
    Completion
    2010-12
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity; Fungal Infection
    InterventionCaspofungin
    PhasePhase 4
    Registry statusCompleted

  • Caspofungin as Prophylaxis in High Risk Liver Transplantation Recipients

    NCT01260974 · start 2009-05

    Registered record
    Registry ID
    NCT01260974
    Conditions
    Fungemia; Mycoses
    Interventions
    Caspofungin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2009-05
    Completion
    2012-11
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFungemia; Mycoses
    InterventionCaspofungin
    PhasePhase 2
    Registry statusUnknown

  • An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Deep Tissue Infection Due To Candida

    NCT00805740 · start 2009-04

    Registered record
    Registry ID
    NCT00805740
    Conditions
    Candidiasis; Fungemia
    Interventions
    Active anidulafungin; Active Caspofungin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2009-04
    Completion
    2012-06
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandidiasis; Fungemia
    InterventionActive anidulafungin; Active Caspofungin
    PhasePhase 3
    Registry statusTerminated

  • Pharmacokinetics of Caspofungin in Burn Patients

    NCT00748345 · start 2009-02

    Registered record
    Registry ID
    NCT00748345
    Conditions
    Thermal Injury
    Interventions
    Caspofungin (drug)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2009-02
    Completion
    2010-12
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThermal Injury
    InterventionCaspofungin (drug)
    PhasePhase 2 / Phase 3
    Registry statusCompleted